ANTI-KRATOM ASSOCIATION

The Drug Enforcement Administration has taken an important step by proposing to temporarily place high-concentration 7-hydroxymitragynine (7-OH) into Schedule I above specified thresholds. The proposal recognizes what has become increasingly obvious: concentrated 7-OH products are potent opioids, have no accepted medical use, present serious risks including dependence and respiratory depression, and are being aggressively marketed in smoke shops and gas stations.

But the proposal also exposes a deeper contradiction.

The DEA acknowledges throughout its notice that 7-OH is a naturally occurring alkaloid in kratom, that it is formed in the body after mitragynine is consumed, and that manufacturers can chemically convert mitragynine into 7-OH.

Then it leaves raw leaf kratom and mitragynine largely untouched for reasons unknown.

The Proposal Depends on Enforcement That Doesn't Exist

The rule sets numerical limits for 7-OH concentrations and attempts to distinguish between products below and above those thresholds.

Who is going to verify that?

• Not the clerk behind the counter.
• Not the gas station owner.
• Not the smoke shop.
• Not the average police officer.

No patrol officer is carrying an LC-MS/MS system in the trunk of a cruiser. Testing requires sophisticated laboratory equipment, trained analysts, and time. By the time laboratory results return, the product has already been sold to hundreds of customers. The practical reality is simple:

The Market Will Adapt

The DEA correctly describes how 7-OH can be produced from mitragynine through relatively simple chemical conversion and notes that concentrated commercial products have proliferated rapidly.

If one formulation disappears, manufacturers redesign products. If one threshold is established, products are formulated just below it or marketed differently. If one molecule is controlled while the parent alkaloid remains widely available, chemistry does the rest.

The Agency's Own Document Raises the Bigger Question

Ironically, the proposal spends page after page describing problems that extend well beyond isolated 7-OH products, such as:

• opioid-like pharmacology,
• aggressive retail marketing,
• colorful products appealing to consumers,
• gas station and smoke shop availability,
• unknown purity,
• inconsistent manufacturing,
• misleading labeling,
• poison center calls,
• overdose reports,
• dependence, and
• products containing multiple opioid alkaloids.

Those are characteristics of the broader commercial kratom market—not simply one isolated molecule.

The document repeatedly describes an industry that has evolved far beyond powdered leaves sold in Southeast Asia, yet the regulatory response targets only part of that evolution.

The Real Test

The measure of this policy will not be the headlines announcing a Schedule I action.

It will be what happens afterward.